A traditional focus of exercise scientists studying the interaction of drugs and exercise has been on the effects of drugs on exercise performance or functional capacity. In contrast, there is limited information available about the effects of exercise on the efficacy of drugs that have been prescribed and ingested for therapeutic reasons. Those requesting the approval for the manufacture, distribution, and sale of new drugs to the public are required to submit evidence of drug effectiveness and safety to drug regulatory bodies. But, there is no associated requirement to include among that evidence the interactions of exercise with drugs. However, the physiological adaptations to acute and chronic exercise are such that there is good reason to suspect that exercise has the potential to significantly influence drug absorption and bioavailability, drug distribution within the body, and drug elimination from the body. This paper reviews the potential for interaction between exercise and pharmacokinetics.
Ira Jacobs, Ethan Ruderman, and Mackenzie McLaughlin
Natalie S. Sherry, Abigail Feder, Raymond Pan, Shawn R. Eagle, and Anthony P. Kontos
. The psychiatrist, R. Pan, started Sarah on sertraline (i.e., brand name Zoloft), a selective-serotonin reuptake inhibitor (SSRI), which is an antidepressant medication used for anxiety symptoms. The SSRIs block the reuptake of the neurotransmitter serotonin into neurons thus increasing the amount of
included individuals with mild, moderate, and severe levels of depression (54% met diagnostic criteria for depression). The antidepressant was sertraline (SSRI), and the primary outcome was the score on a nine-item questionnaire of depressive symptoms at 6 weeks. The effect of the drug did not differ from
Austin J. Graybeal, Brooke Helms, Katie Couris, Daphne Thomas, Tatum Johnston, Victoria Dahan, Nina Escobedo, and Jada L. Willis
, 40 ( 8 ), 691 – 697 . https://doi.org/10.1080/j.1440-1614.2006.01869.x 10.1080/j.1440-1614.2006.01869.x Carney , R.M. , Freedland , K.E. , Rubin , E.H. , Rich , M.W. , Steinmeyer , B.C. , & Harris , W.S. ( 2009 ). Omega-3 augmentation of sertraline in treatment of depression in